meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 1st line (L1)
11
mRCC - L1 - PDL1 negative
1
mRCC - L1 - PDL1 positive
4
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
versus all
vs VEGF(R) inhibitor
vs sunitinib
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
objective responses (ORR)
progression or deaths (PFS)
objective responses (ORR)
mRCC - L1 - PDL1 negative
metastatic/advanced RCC (mRCC) - 1st line (L1)
mRCC - L1 - PDL1 negative
versus sunitinib
atezolizumab plus bevacizumab vs. sunitinib
1
1.06
[0.74; 1.52], 1 RCT, I2=0%
inconclusive result
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open